Docality.com Logo
 
Dr. Charan  Singh  Md image

Dr. Charan Singh Md

2243 Mowry Ave Suite D
Fremont CA 94538
510 958-8000
Medical School: Other - 1988
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: No
License #: BS3515864
NPI: 1821046319
Taxonomy Codes:
2084N0400X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Charan Singh is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99291 Description:Critical care first hour Average Price:$591.00 Average Price Allowed
By Medicare:
$231.42
HCPCS Code:95819 Description:Eeg awake and asleep Average Price:$817.00 Average Price Allowed
By Medicare:
$466.09
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$443.00 Average Price Allowed
By Medicare:
$219.97
HCPCS Code:95934 Description:H-reflex test Average Price:$276.50 Average Price Allowed
By Medicare:
$84.92
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$357.00 Average Price Allowed
By Medicare:
$177.69
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$314.00 Average Price Allowed
By Medicare:
$156.25
HCPCS Code:95861 Description:Muscle test 2 limbs Average Price:$310.00 Average Price Allowed
By Medicare:
$161.59
HCPCS Code:99222 Description:Initial hospital care Average Price:$287.00 Average Price Allowed
By Medicare:
$142.51
HCPCS Code:95819 Description:Eeg awake and asleep Average Price:$177.63 Average Price Allowed
By Medicare:
$59.66
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$234.00 Average Price Allowed
By Medicare:
$116.91
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$218.00 Average Price Allowed
By Medicare:
$108.04
HCPCS Code:95886 Description:Musc test done w/n test comp Average Price:$210.00 Average Price Allowed
By Medicare:
$101.52
HCPCS Code:99221 Description:Initial hospital care Average Price:$210.00 Average Price Allowed
By Medicare:
$104.96
HCPCS Code:99219 Description:Initial observation care Average Price:$235.00 Average Price Allowed
By Medicare:
$139.60
HCPCS Code:95903 Description:Motor nerve conduction test Average Price:$168.00 Average Price Allowed
By Medicare:
$88.43
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$152.00 Average Price Allowed
By Medicare:
$75.46
HCPCS Code:95900 Description:Motor nerve conduction test Average Price:$147.00 Average Price Allowed
By Medicare:
$76.60
HCPCS Code:95904 Description:Sense nerve conduction test Average Price:$130.00 Average Price Allowed
By Medicare:
$67.82
HCPCS Code:99226 Description:Subsequent observation care Average Price:$163.00 Average Price Allowed
By Medicare:
$109.14

HCPCS Code Definitions

95819
Electroencephalogram (EEG); including recording awake and asleep
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
95886
Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; complete, five or more muscles studied, innervated by three or more nerves or four or more spinal levels (List separately in addition to code for primary procedure)
95861
Needle electromyography; 2 extremities with or without related paraspinal areas
95819
Electroencephalogram (EEG); including recording awake and asleep
99291
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99226
Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99222
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.
99221
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of low severity. Typically, 30 minutes are spent at the bedside and on the patient's hospital floor or unit.
99219
Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission to "observation status" are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1790700987
Internal Medicine
2,077
1386608065
Diagnostic Radiology
1,432
1700840238
Diagnostic Radiology
1,324
1154344919
Cardiovascular Disease (Cardiology)
1,311
1598729287
Diagnostic Radiology
1,106
1629180310
Internal Medicine
1,096
1255395398
Diagnostic Radiology
1,056
1235163866
Internal Medicine
946
1760578033
Internal Medicine
943
1235225558
Pathology
931
*These referrals represent the top 10 that Dr. Singh has made to other doctors

Publications

Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. - Carbohydrate polymers
The present study was envisaged to evaluate the effect of erlotinib β-cyclodextrin nanosponge (ERL-NS) on the solubility, dissolution, in vitro cytotoxicity and oral bioavailability of erlotinib (ERL). Preliminary studies were conducted to select the optimized stoichiometry concentration of ERL and NS. The drug nanosponge complex comprising of 1:4 proportions of ERL and NS was prepared by freeze drying. ERL-NS formed nanoparticles of 372±31nm size with narrow size distribution (0.21±0.07 PDI) and high zeta potential (-32.07±4.58mV). The complexation phenomenon was confirmed by DSC, SEM, PXRD, FTIR, and TEM studies. In vitro dissolution studies revealed an increased dissolution rate (2-folds) with an enhanced dissolution efficiency of the nanosponge complex in comparison to pure drug. In vitro cytotoxicity study and apoptosis assay in pancreatic cell lines (MIA PaCa-2 and PANC-1) indicates the increased toxicity of ERL-NS. Both, quantitative and qualitative cell uptake studies unveiled the higher uptake efficiency of ERL-NS than free drug. ERL-NS showed enhanced oral bioavailability with 1.8-fold higher Cmax (78.98±6.2 vs. 42.36±1.75μg/ml), and ∼2-fold AUC0-∞ (1079.95±41.38 vs. 580.43±71.91), in comparison to pure ERL. Therefore, we conclude that the formation of a complex of nanosponge with ERL is a successful approach to increase its solubility, dissolution and oral bioavailability which may ultimately result in reduction in dose and dose related side-effects.Copyright © 2015 Elsevier Ltd. All rights reserved.
Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation. - Carbohydrate polymers
The aim of the study was to investigate the impact of erlotinib sulfobutyl ether beta-cyclodextrin complex (ERL-SBE-β-CD) on ERL dissolution rate and oral bioavailability. Preliminary comparative phase solubility study indicated ERL exhibited maximum solubility in SBE-β-CD solution. Optimal experimental design confirmed freeze drying of SBE-β-CD:ERL in 1:1.05 molar ratio as the optimum method. Differential scanning calorimetry (DSC), Fourier transformation infrared spectroscopy (FT-IR), powder X-ray diffractometry (PXRD), proton nuclear magnetic resonance ((1)H NMR) and two-dimensional rotating-frame Overhauser effect spectroscopy (2D ROESY NMR) confirmed the inclusion complexation. The in silico computational study, employed to analyze the comparative interactions of ERL with SBE-β-CD and β-CD, indicated ease of ERL-SBE-β-CD complexation. In vitro dissolution and in vivo bioavailability studies further confirmed the ERL-SBE-β-CD as a valuable approach to enhance ERL oral bioavailability with 3.6-fold increase in relative oral bioavailability with higher Cmax (134.29 ± 36.51 vs. 42.36 ± 1.75 μg/ml) and AUC0-∞ (2103.47 ± 156.75 vs.580.43 ± 71.91 μg/ml h) over the free drug. The complex exhibited 3.2-fold increase in Cmax with 5.4-fold decrease in Tmax (0.5 ± 0.2 vs. 2.7 ± 0.8h) in comparison to pure ERL. Thus, ERL-SBE-β-CD complexation exhibits a potential to enhance oral bioavailability of ERL leading to reduce dose and dose-related side effects.Copyright © 2015 Elsevier Ltd. All rights reserved.
Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution. - International journal of pharmaceutics
The aim of the present study was to establish the potential of rifampicin loaded phospholipid lipospheres carrier for pulmonary application. Lipospheres were prepared with rifampicin and phospholipid in the ratio of 1:1 using spray drying method. Further, lipospheres were evaluated for flow properties and surface area measurement. The formulated lipospheres were evaluated in vitro for aerodynamic characterization and in vivo for lung pharmacokinetics and biodistribution studies in Sprague Dawley rats. Powder flow properties finding suggested the free flowing nature of the lipospheres. In-vitro aerosol performance study indicated more than 80±5% of the emitted dose (ED) and 77.61±3% fine particles fraction (FPF). Mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were found to be 2.72±0.13μm and 3.28±0.12, respectively. In-vitro aerosol performance study revealed the higher deposition at 3, 4 and 5 stages which simulates the trachea-primary bronchus, secondary and terminal bronchus of the human lung, respectively. The drug concentration from nebulized lipospheres in the non-targeted tissues was lesser than from rifampicin-aqueous solution. The pulmonary pharmacokinetic study demonstrated improved bioavailability, longer residence of drug in the lung and targeting factor of 8.03 for lipospheres as compared to rifampicin-aqueous solution. Thus, the results of the study demonstrated the potential of rifampicin lipospheres formulation would be of use as an alternative to existing oral therapy.Copyright © 2015 Elsevier B.V. All rights reserved.
Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability. - International journal of pharmaceutics
In the present study, tamoxifen-phospholipid complex (TMX-PLC) was developed and evaluated for its impact on solubility and bioavailability of tamoxifen. TMX-PLC was prepared by solvent evaporation method and characterized. FTIR revealed the disappearance of the characteristic peaks of TMX in the complex, which can be due to weakening, removal or shielding by the phospholipid molecule. This phenomenon could be due to packing of TMX in the hydrophobic cavity of phospholipid and being held by van der Waals forces and hydrophobic interactions. This observation was confirmed by DSC and PXRD. TMX-PLC exhibited increased solubility, dissolution rate with decreased distribution coefficient indicating its increased hydrophilicity. Oral bioavailability of TMX and TMX-PLC were evaluated in Sprague-Dawley (SD) rats. TMX-PLC exhibited considerable enhancement in the bioavailability with an increase in Cmax (0.85 vs. 0.40 μg/mL), t1/2 (22.47 vs. 13.93 h), and AUC0-∞ (15.29 vs. 8.62 μg h/mL) with 212.25% relative bioavailability. This enhancement can be attributed to the improvement of the aqueous solubility of the complex and a probable decrease in its extent of intestinal and hepatic metabolism. Thus, phospholipid complexation holds a promising potential for increasing oral bioavailability of TMX.Copyright © 2014 Elsevier B.V. All rights reserved.
Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. - International journal of pharmaceutics
To enhance the oral bioavailability of rifampicin (RMP), the newly emerging phospholipid complexation technique was employed. Rifampicin-phospholipid complex (RMP-PC) was prepared by solvent-evaporation method. Infrared spectroscopy (IR), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and hot stage microscopy (HSM) analysis were employed to confirm the formation of phospholipid complex. The results reveal hydrogen bond formation and electrostatic interaction between RMP and phospholipid molecule play an important role in the formation of RMP-PC without the formation of a new compound. In comparison with the physical mixture and RMP, solubility studies indicated an enhancement in the aqueous solubility of RMP-PC. Stability studies of RMP-PC in presence of isoniazid showed a remarkable improvement of the stability of the phospholipid complex in comparison to free RMP. Oral bioavailability of RMP-PC was evaluated in Sprague-Dawley (SD) rats and plasma rifampicin estimated by LCMS. RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug. This enhancement can be attributed to the improvement of the aqueous solubility of rifampicin-phospholipid complex. Hence, phospholipid complexation holds a promising potential for increasing oral bioavailability of poorly water soluble drugs.Copyright © 2013 Elsevier B.V. All rights reserved.
Thermally stable nonaggregating pyrenylarenes for blue organic light-emitting devices. - The Journal of organic chemistry
A new series of thermally stable blue light-emitting nonplanar pyrenylarenes having an amine donor and a nitrile acceptor group was prepared from a ketene-S,S-acetal under conventional heating and/or microwave irradiation. The photophysical, electrochemical, and optical behavior of donor-acceptor pyrenylarenes are demonstrated. The performance of blue light-emitting pyrenylarenes was investigated by fabricating a multilayer device with the device configuration of ITO/PEDOT:PSS (40 nm)/NPB (30 nm)/pyrenylarene (55 nm)/BCP (8 nm)/LiF (0.6 nm)/Al (200 nm), which exhibited low turn-on voltage (5 V) with luminance efficiency of 0.8 Cd/A with nonaggregation behavior in both solution and solid state.© 2011 American Chemical Society
Status of iodine content of salt in four regions of India. - Indian journal of pediatrics
To study the Status of Iodine Content of Salt in four regions of India.At each of the four centers (Vadodara, Dibrugarh, Jodhpur, New Delhi), High Schools were selected randomly from list of schools obtained from district education office and more than 700 salt samples were selected from each center. A total of 3,010 salt samples were collected from students of High Schools (consumed at their households), selected randomly from four centers and iodine content of salt by Standard Iodometric Titration Method (IT) was estimated.Analysis revealed that majority of salt sample collected at 4 centers were of powdered variety of salt. Analysis of iodine content in salt by IT method revealed that high proportion of school children (51.6%) consumed salt having inadequate iodine content (salt samples with less than 15 ppm of iodine) in Jodhpur district followed by Vadodara (19.8%), New Delhi (8.5%) and least in Dibrugarh (1.2%). The percentage of consumption of adequately iodized salt was highest in Dibrugarh (98.8%) among the four regions of India.Status of iodine content is varying from state to state i.e. highest at Dibrugarh and lowest at Jodhpur. This indicates that consumption of iodized salt in Jodhpur is low and needs more attention. Government may adopt different strategies in different states. There is a strong need of iodization of salt in addition to creating awareness among rural inhabitants for consumption of iodized salt especially in Jodhpur District. More attention is required for monitoring quality of iodized salt available in the community.
Changes in colostrum of Murrah buffaloes after calving. - Tropical animal health and production
Colostrum samples were collected from 8 Murrah buffaloes on days 1, 2, 3, 4 and 5 after calving. Levels of IgG averaged 54.0 mg/ml at calving, then decreased significantly (P < 0.01). IgA and IgM on day 1 were 3.22 mg/ml and 5.22 mg/ml, respectively; both decreased during the first five days after calving. Values of IgA and IgM were higher than those reported in cows. SCC values, which were high at calving (500,000 per ml), reduced significantly (P < 0.01) on day 2, then decreased slightly until day 5 (180,000 per ml). At calving, macrophages were the most prominent cells in buffalo colostrum, followed by lymphocytes and neutrophils. Phagocytic activity was 23% at calving and reduced significantly (P < 0.01) to 14% on day 5. Phagocytic index was highest in the first colostrum, and then decreased non-significantly.
Assessment of iodine deficiency disorders in district Bharatpur, Rajasthan. - Indian pediatrics
Iodine deficiency disorders (IDD) is a public health problem in India. A ban on the sale of uniodised salt for household consumption has been introduced in Rajasthan State since 1992. The present study was conducted in the district of Bharatpur, Rajasthan with the objective to assess the prevalence of iodine disorders in school children as no data is available on this aspect. A total of 3072 children in the age group of 6-12 years were included in the study and were clinically examined. On the spot urine samples were collected randomly from 450 children. A total of 1064 salt samples were collected randomly from the families of the children. The total goiter prevalence was found to be 7.2% in the subjects studied. It was found that the percentage of children with urinary iodine excretion <20.0; 20.0-49.9, 50.0-99.9 and 100 mcg/L and above was 1.1, 1.1, 7.8 and 90.0% respectively. The assessment of iodine content of salt revealed that 56% of the families were consuming iodised salt. The findings of the present study indicated that the population is in a transition phase from iodine deficient (as revealed by the TGR) to iodine sufficient (as revealed by the medium UIE of 200.0 mcg/L) nutriture.
Development of Novel Polymer-Lipid Hybrid Nanoparticles of Tamoxifen: In Vitro and In Vivo Evaluation. - Journal of nanoscience and nanotechnology
This study was undertaken to develop and investigate the effect of tamoxifen polymer-lipid hybrid nanoparticles (Tmx-PLN) on its oral bioavailability and efficacy in the 7,12-dimethylbenzanthracene (DMBA)-induced breast cancer model. Modified solvent emulsification-evaporation method was optimized to obtain Tmx-PLN, composed of chitosan and lecithin, of 169.66 ± 4.84 nm particle size. The PLN exhibited prolonged in vitro release in phosphate-buffered saline. Further, PLN displayed enhanced oral bioavailability with considerable increase in AUC (1277.46 vs. 585.01 ng/ml · h), pro- longed t½ (27.87 ± 15.62 vs. 10.18 ± 6.5 h) and mean residence time (40.11 ± 25.72 vs. 17.42 ± 12.04 h) in comparison to pure Tmx. In addition, PLN exhibited significantly increased (P < 0.05) antitumor efficacy in DMBA-induced breast cancer model, when administered once in three days in comparison to Tmx daily dosing. This enhancement may be attributed to a probable reduction in Pgp efflux, decreased first-pass metabolism and lymphatic drug transport. Thus, Tmx-PLN exhibited enhanced potential to increase Tmx therapeutic efficacy in chronic treatment of breast cancer.

Map & Directions

2243 Mowry Ave Suite D Fremont, CA 94538
View Directions In Google Maps

Nearby Doctors

3200 Kearney St
Fremont, CA 94538
510 901-1222
39200 Liberty St Suite D
Fremont, CA 94538
510 979-9711
39400 Paseo Padre Pkwy
Fremont, CA 94538
510 953-3000
39400 Paseo Padre Pkwy
Fremont, CA 94538
510 953-3000
40000 Fremont Blvd Ste A
Fremont, CA 94538
650 781-1387
2299 Mowry Ave
Fremont, CA 94538
510 915-5374
39400 Paseo Padre Pkwy
Fremont, CA 94538
510 953-3000
3200 Kearney St
Fremont, CA 94538
510 901-1222
3200 Kearney St
Fremont, CA 94538
510 901-1222
39400 Paseo Padre Pkwy
Fremont, CA 94538
510 483-3000